[Latest] Global PARP Inhibitors Market Size/Share Worth USD 23.5 Billion by 2032 at a 12.1% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
March 27, 2024 14:30 ET
|
Custom Market Insights
Austin, TX, USA, March 28, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “PARP Inhibitors Market Size, Trends and Insights By Type (Olaparib, Rucaparib,...
Prostate Cancer Drugs Global Market Report 2024: Emerging Combination Therapies and Geographic Expansion to Propel the Global Prostate Cancer Drugs Market Through 2028
January 22, 2024 16:58 ET
|
Research and Markets
Dublin, Jan. 22, 2024 (GLOBE NEWSWIRE) -- The "Prostate Cancer Drugs Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering. This recent comprehensive study sheds...
Olaparib Reduces Organ Damage in Sepsis
September 13, 2021 10:00 ET
|
Experimental Biology and Medicine
WASHINGTON, Sept. 13, 2021 (GLOBE NEWSWIRE) -- A recently published article in Experimental Biology and Medicine (Volume 246, Issue 17, September, 2021) examines the role of olaparib in sepsis. The...
Cyclacel Announces Presentation of Phase 1 Data of Sapacitabine Regimen in Patients With BRCA Mutant Breast Cancer at AACR 2019
April 01, 2019 07:00 ET
|
Cyclacel
BERKELEY HEIGHTS, N.J., April 01, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing innovative...
Cyclacel Pharmaceuticals Announces Initiation of Phase 1b/2 Clinical Trial of Sapacitabine With Olaparib in BRCA Mutant Breast Cancer
September 10, 2018 07:00 ET
|
Cyclacel
BERKELEY HEIGHTS, N.J., Sept. 10, 2018 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...